Overview of Dr. Eroglu
Dr. Zeynep Eroglu is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. She received her medical degree from David Geffen School of Medicine at UCLA and has been in practice 9 years. She is one of 170 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. She has more than 90 publications and over 500 citings.
Office
10920 McKinley Dr
Tampa, FL 33612
Education & Training
- Los Angeles County-Harbor-UCLA Medical Center 1Fellowship, Hematology and Medical Oncology, 2012 - 2015
- University of California (Irvine)Residency, Internal Medicine, 2008 - 2011
- David Geffen School of Medicine at UCLAClass of 2008
Certifications & Licensure
- CA State Medical License 2010 - 2025
- FL State Medical License 2015 - 2025
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma Start of enrollment: 2016 Sep 07
- Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma Start of enrollment: 2018 Jun 27
- Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma Start of enrollment: 2018 Jun 14
- Join now to see all
Publications & Presentations
PubMed
- 284 citationsSafety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.Megan H. Pollack, Allison S. Betof, Helen Dearden, K. Rapazzo, I. Valentine
Annals of Oncology. 2018-01-01 - 1567 citationsFatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysisDaniel Y. Wang, Joe-Elie Salem, Justine V. Cohen, Sunandana Chandra, Christian Menzer
JAMA Oncology. 2018-12-01 - 598 citationsAnti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumabAlexander M. Menzies, Douglas B. Johnson, S. Ramanujam, Victoria Atkinson, Annie Wong
Annals of Oncology. 2017-02-01
Journal Articles
- Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-cell PopulationsZeynep Eroglu, Iman Osman, Theodore S Nowicki, Antoni Ribas, Michael A Davies, Farbod Darvishian, Daniel Y Wang, Douglas B Johnson, Ravi K Amaravadi, Clinical Cancer Research
Lectures
- Phase I study of vemurafenib (VEM) and cobimetinib (COB) with heat shock protein 90 (HSP90) inhibitor XL888 in advanced BRAFV600 mutant melanoma.2019 ASCO Annual Meeting - 6/1/2019
- Retrospective analysis of patients with sentinel lymph node (SLN) positive melanoma (MEL) who received adjuvant nivolumab (NIVO) without completion lymph node dissecti...2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
- Desmoplastic Melanoma Highly Responsive to ImmunotherapyMay 11th, 2023
- Desmoplastic Melanoma Responds to Pembrolizumb MonotherapyApril 20th, 2023
- Woman's Breast Tumor Turned Out to Be Melanoma. But There Was Never a MoleMarch 13th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: